Description: Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response to the company’s agreed acquisition of Exact Sciences. In the largest acquisition in the medtech sector thus far this year, Abbott Laboratories (NYSE:ABT) signed […]

Description: Abbott Laboratories’ stock narrative is shifting as analysts adjust their consensus price target, which has edged down slightly from $144.47 to $144.43. This recent update comes alongside a range of views shaped by the company’s varied business performance and strategic moves. Stay tuned to see how you can monitor these market perspectives and keep up with evolving updates on Abbott’s outlook. Stay updated as the Fair Value for Abbott Laboratories shifts by adding it to your watchlist or...

Description: GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo

Description: The North America Heart Pump Device market is projected to grow from USD 2.92 billion in 2024 to USD 8.1 billion by 2033, reflecting a CAGR of 12% between 2025-2033. Key drivers include technological advancements, increasing heart disease prevalence, and a rising geriatric population. Devices like LVADs and total artificial hearts are crucial in treating advanced heart failure. The U.S. leads with a well-funded healthcare system, while Canada's universal healthcare supports access. Challenges in

Description: The Pediatric Interventional Cardiology Market is poised for significant growth, projected to rise from USD 2.42 billion in 2024 to USD 4.34 billion by 2033, exhibiting a 6.68% CAGR. This expansion is driven by the increasing prevalence of congenital heart defects such as VSD, PDA, and ASD in children. The advent of advanced medical devices and the shift towards non-invasive treatments also contribute to market growth. The U.S. stands out as a key player due to rising infant cardiac abnormalitie

Description: The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Description: Abbott Laboratories (ABT) stock has caught the attention of investors after recent trading momentum shifted slightly upward this week. This move comes on the back of moderate gains over the past month, encouraging some renewed interest in the healthcare giant. See our latest analysis for Abbott Laboratories. This week’s upward momentum follows what has been a solid stretch for Abbott Laboratories, underscoring renewed optimism after a year of moderate but positive performance. While the share...

Description: Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Description: Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls

Description: BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Description: The Autoimmune Disease Diagnostics industry is set for significant growth, projected to leap from US$ 5.70 billion in 2024 to US$ 10.63 billion by 2033, at a CAGR of 7.17%. Key growth drivers include a rising need for precise diagnostic tools and a focus on enhanced patient outcomes. Innovations in diagnostic technologies and strategic partnerships among industry leaders are paving the way for improvements. Leading companies like Abbott Laboratories, Bio-Rad, Roche Diagnostics, and Siemens Healt

Description: Booking, Carvana upgraded: Wall Street's top analyst calls

Description: With its stock down 2.6% over the past three months, it is easy to disregard Abbott Laboratories (NYSE:ABT). But if you...

Description: Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently offered insights on. Cramer highlighted the company’s acquisition of Exact Sciences and said that it complements Abbott’s diagnostic business, as he remarked: “This morning, Abbott Labs announced that it’s buying Exact Sciences, that’s the colorectal cancer screening company, for about $21 billion. It’s a […]

Description: We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer discussed. This show marked more than a month after Cramer discussed pharmaceuticals and diagnostics devices firm Abbott Laboratories (NYSE:ABT). However, the delay doesn’t mean he’s changed his sentiment about the firm. Cramer often calls Abbott Laboratories […]

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: These healthcare stocks have long-term and profitable growth runways.

Description: Find insight on Abbott, Ryman Healthcare, Novartis and more in the latest Market Talks covering the health care sector.

Description: Earlier this month, Exact reported a record $851 million in third-quarter revenue, which included $666 million from its screening business.

Description: With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Description: The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.

Description: These companies have been raising their payouts for a combined 101 consecutive years.

Description: The transaction includes the absorption of Exact Sciences’ estimated net debt of $1.8bn.

Description: Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.

Description: 0939 ET – Abbott’s commercial infrastructure makes it a good fit for Exact Sciences, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today. “Abbott controls the largest primary care-facing point-of-care diagnostics footprint globally,” Jennings says. Additionally, Abbott’s large salesforce for its continuous glucose monitor products could be leveraged to boost sales through the primary care provider channel.

Description: ↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.

Description: Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.

Description: Exact Sciences stock rocketed for a second day Thursday, after Abbott Laboratories confirmed a $23 bil. buyout deal.

Description: Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C

Description: The company received a buyout offer from Abbot Labs.

Description: Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow Abbott — which makes medical tests, baby formula and continuous glucose monitors, among other products — to enter the cancer testing space. Exact Sciences focuses on early cancer detection and personalized treatments, and ...

Description: Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Description: A healthcare giant covets the cancer screening leader's technology.

Description: Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer is a colonoscopy.

Description: The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the biggest healthcare acquisition announced this the year, and would be Abbott’s largest since 2017. Abbott will pay $105 per share of Exact Sciences, a 50% premium over Exact Sciences’ closing price on Tuesday of $69.68.

Description: All three major US stock indexes were up in late-morning trading after Nvidia (NVDA) reported strong

Description: Deal boosts ABT's cancer-screening footprint and long-term growth

Description: Abbott Laboratories (ABT) agreed to acquire cancer screening and diagnostics tests provider Exact Sc

Description: If you have ever wondered whether Abbott Laboratories is trading for more or less than its true value, you are in the right place. The stock has returned 11.2% year to date and 10.9% over the past 12 months, despite recent minor pullbacks of 2.1% in the last week and 2.6% in the last month. Recent headlines have focused on Abbott's continuous innovation in medical devices and its steady expansion into global healthcare markets. Industry analysts have also highlighted the company's strategic...

Description: Abbott Laboratories agreed to acquire cancer diagnostics company Exact Sciences in a deal valued at about $21 billion, as Abbott looks to compete in the burgeoning market for multi-cancer early detection tests. Exact Sciences shareholders will receive $105 a share. The stock rose 17.9% to $101.60 in morning trading after closing at $86.18 Wednesday.

Description: US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Abbott Laboratories' (ABT) move to buy Exact Sciences (EXAS) in a $21 billion deal, reports that Verizon Communications (VZ) will be cutting over 13,000 jobs in its restructuring, and Bath & Body Works (BBWI) shares sinking after the brand cut its full-year earnings forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal valued at approximately $21 billion.

Description: A strategic investor is reportedly in advanced talks to purchase the company.

Description: Exact Sciences stock catapulted Wednesday on a report that Abbott Laboratories is nearing a deal to buy the cancer-finding specialist.

Description: Shares of the cancer diagnostics company Exact Sciences surged 25% late Wednesday, after a report said the conglomerate Abbott Laboratories is close to a deal to acquire the company. Neither Abbott nor Exact Sciences immediately responded to a request for comment. The Bloomberg report didn’t include any financial terms of a potential deal.

Description: Investing.com -- Shares of Exact Sciences are soaring over 21% on Wednesday following a Bloomberg report that Abbott Laboratories is in advanced talks to acquire the medical-testing company.

Description: Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Description: Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Description: Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Description: HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.

Description: Buying a low-cost index fund will get you the average market return. But across the board there are plenty of stocks...

Description: These stocks pay income that investors can count on over the long run.

Description: Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...

Description: Here are five Goldman Sachs stock picks that conservative growth and income investors should consider moving to for what could be a volatile 2026.

Description: Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.

Description: Founder and Chief Executive Officer Will Ahmed said the business is well-positioned for an IPO now that it’s broadened its portfolio to include proprietary technology, hardware, software, analytics and other items, such as accessories and apparel. While Ahmed has previously said Whoop is likely to go public, he hadn’t shared when that might happen. “We like to build things ourselves and we really want to build this home of health for our members,” he added.

Description: The United States Dietary Supplements Market, projected to grow from US$ 54.24 billion in 2024 to US$ 103.56 billion by 2033, is driven by rising health awareness and demand for preventive healthcare, alongside growing fitness trends and an aging population. Busy lifestyles, online retail expansion, and innovation in supplement formulations further stimulate market growth. Popular for their role in enhancing immunity, fitness, and general health, dietary supplements include vitamins, minerals, a

Description: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the […]

Description: J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.

Description: This story has been updated to reflect the FDA's November 11, 2025, announcement. The baby formula market is dominated by a handful of companies, including Abbott Labs, Mead Johnson, and Nestle. Together, these companies account for more than 80% of the infant formula market in the U.S., according ...

Description: Abbott Laboratories (NYSE:ABT) is included among the 15 Best Dividend Growth Stocks to Buy Now. On October 24, Citi a‌nalyst Joanne Wuensch reaffirmed a Buy rating on​ Abbott Laboratories (NYSE:ABT), as reported by The Fly. She highlighted​ t‌h‍at Judg⁠e Pallmeyer of‌ the US Distr‌ict Court f‍or the Nort‍hern District of Illinois granted summary judgme⁠nt in […]

Description: Abbott Laboratories (ABT) just released its quarterly results, revealing revenue grew nearly 7% over last year, though it missed Wall Street estimates. The company kept its full-year outlook intact and narrowed adjusted EPS guidance. See our latest analysis for Abbott Laboratories. Abbott Laboratories’ 1-day share price return of 1.13% suggests investors remain upbeat after its latest report, even with revenue coming in below expectations. While momentum has softened recently, with a 30-day...

Description: In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...

Description: PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi

Description: These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.

Description: It’s been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.

Description: "Driven by Technological Advances and Expanding Clinical Applications, Patient Monitoring Devices Are Revolutionizing Healthcare Delivery Across Hospitals, Home Care, and Remote Settings"Boston, Nov. 07, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Patient Monitoring Devices: Global Markets” is projected to grow from $36.7 billion in 2025 to $55.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2025 to 2030.

Description: Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Description: Wondering if Abbott Laboratories is undervalued, fairly priced, or perhaps even a hidden bargain? You are not alone, as many investors are taking a closer look at this healthcare giant. The stock is up 9.8% year-to-date, despite a recent 6.9% dip in the last month. This highlights how sentiment and risk perception can change quickly. Investors have been reacting to headline-grabbing developments such as innovations in Abbott's medical device segment and new product...

Description: BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.

Description: Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Market trends indicate robust expansion in online retail, convenience stores, and prepared baby food segments. Leading countries like China and India bolster growth, with key players including Nestlé and Danone at the forefront. Asia-Pacific Organic Baby Food Market Asia-Pacific Organic Baby Food Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Organic Baby Food Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.co

Description: This holiday season, global healthcare leader Abbott is adding even more heart to Hallmark Channel's beloved "Countdown to Christmas" lineup with a story that features a special community and is sure to spread joy and inspiration. "The More the Merrier," a new original Hallmark movie, features real-life heroes from Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during Hallmark's Merry Thanksgiving Weekend during "Co

Description: Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin

Description: Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...

Description: The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an

Description: The HbA1c testing market presents opportunities driven by rising Type 2 diabetes cases and advancements in testing technologies. Supportive healthcare initiatives and increased awareness enhance demand. Strategic insights, competitive analysis, and diverse applications across settings highlight key investment areas. HbA1c Testing Market HbA1c Testing Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "HbA1c Testing Market Size, Share, Growth, Trends and Forecast 2025-2033" report has been adde

Description: Abbott Laboratories has seen its consensus analyst price target notch a slight increase, moving from $144.40 to $144.47, as updated research lends fresh nuance to the company's outlook. This modest adjustment reflects a blend of analyst optimism fueled by favorable legal developments and ongoing strength in its Medical Devices segment. However, there are also pockets of caution stemming from mixed quarterly results. Stay tuned to discover how investors and observers can stay ahead as the...

Description: Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

Description: Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media. NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- A revolutionary advancement in cardiac care is changing what’s possible for people living with slow or abnormal heart rhythms. On O

Description: Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.

Description: The AI rally has many investors wondering where to turn in anticipation of its end. The medical-device maker is one solid option.

Description: Zacks analysts highlight IBM, Micron, and Abbott for their innovation-driven growth, solid fundamentals, and evolving market strategies.

Description: IBM posts strong Q3 results as Watsonx and quantum bets boost growth, while Micron rides AI-driven memory demand and Abbott expands on device strength.

Description: SAN DIEGO, October 29, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes w

Description: DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.

Description: Key Insights The projected fair value for Abbott Laboratories is US$95.46 based on 2 Stage Free Cash Flow to Equity...

Description: The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card

Description: Founded in 1869, Goldman Sachs is the world’s second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue. The Wall Street white-glove giant offers financing, advisory services, risk distribution, and hedging for the firm’s institutional and corporate clients. We review the firm’s ... Goldman Sachs Still Says Sell-Off Coming – 5 Safe Conviction List Picks

Description: Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month. However, year to date, the company has delivered an 11% gain, reflecting underlying strength in its business. See our latest analysis for Abbott Laboratories. After a steady climb earlier this year, Abbott Laboratories’ share price momentum has cooled off a bit, with the recent 1-month share price return of -7% standing out against an otherwise solid 11% year-to-date gain...

Description: The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Description: Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: There's a shift towards plant-based sources like pea, soy, and quinoa, appealing to clean-label and allergen-free seekers. Innovations such as ready-to-drink beverages and gummies are expanding market appeal. North America leads, backed by strong fitness culture, while APAC shows the fastest growth. The market is highly fragmented with key players like Abbott, Glanbia, and Nestlé. E-commerce platforms are transforming distribution, offering convenience and variety. Global Protein Supplements Mar

Description: Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to double-digit growth in medical devices, led by diabetes care and electrophysiology, as key drivers for the quarter. CEO Robert Ford commented that “recently launched new products generated nearly $5 billion in sales this quarter,” highlighting the contribution of new offerings. However, ongoing head

Description: The Global Functional Foods Market is set to expand at a CAGR of 7.92% from 2025 to 2033, reaching $678.32 billion by 2033, up from $341.6 billion in 2024. The surge is driven by increasing health awareness, demand for fortified foods, and an emphasis on preventive healthcare. Functional foods, enhanced with vitamins, minerals, and probiotics, are gaining traction among health-conscious consumers aiming to prevent chronic diseases. Key markets include the U.S., Germany, and India, with bakery an

Description: Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in. Benchmark began coverage of Abbott Laboratories (NYSE:ABT) on October 10 with a $145 price target and a Buy rating, describing the company as a reliable performer in a dynamic global environment. The firm claims that Abbott’s business strategy is unique in that […]

Description: The global home healthcare market is projected to reach USD 473.8 billion by 2030, up from USD 309.9 billion in 2025, growing at a CAGR of 8.9%. This expansion is driven by rising lifestyle-related disorders such as high blood pressure, obesity, and cardiac conditions. Leading companies are innovating and introducing new home healthcare products. The therapeutic products segment holds the largest market share, fueled by a growing prevalence of chronic health conditions. Skilled nursing services

Description: In October 2025, Abbott Laboratories reported third-quarter results showing US$11.37 billion in sales and reaffirmed its 2025 earnings guidance, narrowing expected full-year adjusted diluted EPS to US$5.12–US$5.18, while guiding for organic sales growth of 7.5%–8.0% excluding COVID-19 testing. Despite strong medical device sales, the company faced mixed results due to challenges in its diagnostics and nutrition segments, prompting investors to focus closely on its revised annual outlook and...

Description: Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one of Malaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness across Malaysia. The Influenza Awareness Program, running from 2025 to 2027, is designed to elevate public understanding of influenza and encourage proactive health management.

Description: Key opportunities in the global patient monitoring devices market include expanding use of miniaturized multi-sensing devices and adoption due to stringent regulations, enhanced self-management of chronic diseases, and growth potential in emerging regions. Sustainability and ESG practices also offer competitive advantages. Patient Monitoring Devices Market Patient Monitoring Devices Market Dublin, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The "Patient Monitoring Devices: Global Markets" report has been

Description: Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

Description: Here are the four new stock additions to the Goldman Sachs Conviction List for October—all outstanding total return ideas for growth and income investors.

Description: Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...